Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

The company last reported total revenues of $108M in Q1, down 35.3% Y/Y due to lower net product sales, particularly its ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, highlighting the need for targeted outreach programs.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age ...